Janssen Pharmaceutica and Iktos have partnered to develop applications for small molecule drug discovery using Iktos' AI-based virtual design technology and Janssen's expertise in AI-based prediction of small-molecule activities. Gaston-Mathé further added: “Iktos has been a pioneer in the application of generative models for drug discovery and is emerging as a world leader in a technology that has the potential to disrupt the way new therapeutics are designed.” The companies will work together on a number of projects including the development of new drugs targeting cancer or other diseases that are difficult to treat with existing drugs.
Janssen Pharmaceutica and Iktos have partnered to develop applications for small molecule drug discovery using Iktos' AI-based virtual design technology and Janssen's expertise in AI-based prediction of small-molecule activities. The companies will work together on a number of projects including the development of new drugs targeting cancer or other diseases that are difficult to treat with existing drugs.